据报Summit与阿斯利康洽谈高达150亿美元合作

格隆汇
Jul 04, 2025

据彭博,阿斯利康正在与Summit Therapeutics讨论一项合作协议,根据该协议,阿斯利康公司可能分期支付高达150亿美元以获得肺癌药物的许可。报道指,两家公司一直在就Summit旗下Ivonescimab疗法的潜在合作进行谈判。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10